摘要
目的观察玄武膝痛颗粒治疗膝关节骨性关节炎(KOA)的临床疗效及对外周血清白细胞介素-1(IL-1)和肿瘤坏死因子-α(TNF-α)的影响。方法将160例KOA患者随机分为2组,对照组80例予西医治疗,治疗组80例在对照组治疗基础上加玄武膝痛颗粒。2组均12周为1个疗程,共治疗3个疗程。统计2组临床疗效,观察2组治疗前后IL-1、TNF-α水平及骨关节炎指数评分量表(WOMAC)评分变化情况。结果治疗组总有效率95.00%,对照组总有效率75.00%,2组总有效率比较差异有统计学意义(P<0.05),治疗组临床疗效优于对照组。2组治疗后IL-1、TNF-α水平及WOMAC疼痛评分、关节僵硬评分、日常活动评分及综合评分均与本组治疗前比较明显下降(P<0.01),且治疗组下降较对照组明显(P<0.05)。结论玄武膝痛颗粒治疗KOA具有较好的临床疗效,降低外周血清IL-1及TNF-α的表达可能是其抗炎镇痛的作用机制之一。
Objective To observe the clinical efficacy of Xuanwu Xitong granules and its effects on IL - 1 and TNF - α in peripheral blood of the knee osteoarthritis （KOA） patients. Methods 160 cases of patients with KOA were randomly divided into two groups. Patients in the control group （ n = 80） were treated with western medi- cine therapy, while the treatment group （80 cases） were treated with Xuanwu Xitong granules on the basis of the control group＇s therapy. The course was 12 weeks in two groups. The changes of the overall efficacy, WOMAC scores, IL - 1 and TNF - α were compared between the two groups after three courses. Results The total effective rate of the treatment group was 98% ,while the control group was only 80% ,the difference between two groups was statistically significant on the total effective rate （ P 〈 0.05 ）. WOMAC scores and the levels of IL - 1 and TNF - a after treat- ment were decreased significantly compared with those before treatment in two groups. However, the degrees of decline in the treatment group were better than the control group （ P 〈 0.05 ）. Conclusion Xuanwu Xitong granules had better clinical efficacy on the treatment of KOA, reducing the expression levels of IL - 1 and TNF - odn peripheral serum could be one of the mechanisms of Xuanwu Xitong granules for anti - inflammatory and analgesic.
出处
《河北中医》
2013年第2期176-178,181,共4页
Hebei Journal of Traditional Chinese Medicine
基金
湖北省卫生厅2011-2012年度中医药
中西医结合科研重点项目(编号:2012Z-Y48)
关键词
骨关节炎
膝
中药疗法
玄参
武靴藤
白细胞介素1
肿瘤坏死因子Α
Knee osteoarthritis
Traditional Chinese medicine therapy
Radix scrophulariae
Gymnema syl- vestre
Interleukin - 1
Tumor necrosis factor - α
